Dr. Cooperberg on Earlier Treatment With Sipuleucel-T
Matthew Cooperberg, MD, MPH
Published Online: Friday, February 15, 2013
Matthew Cooperberg, MD, MPH, Assistant Professor of Urology; Epidemiology & Biostatistics, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the earlier administration of treatment with sipuleucel-T (Provenge) for men with prostate cancer.
Cooperberg believes that immunotherapies, such as sipuleucel-T, are best administered earlier in the treatment paradigm when the immune system is stronger and less cancer cells are present.
To examine this, a study conducted at the University of California, San Francisco looked at the neoadjuvant administration of sipuleucel-T. The primary endpoints for this study were immune parameters that related to immune activation by sipuleucel-T. Cooperberg believes that from a mechanistic standpoint, sipuleucel-T may be most effective when given as a neoadjuvant therapy in prostate cancer.
Richard R. Furman, MD, from the New York Weill Cornell Medical Center, discusses the ability to avoid the administration of chemotherapy when using novel agents, such as idelalisib, to treat patients with chronic lymphocytic leukemia.